P2-435 Specific risk factors associated with coronary heart disease in Indians

Abstract Objective: To investigate the prevalence and related risk factors associated with coronary heart disease（CHD） among middle aged and elderly patients with vision impairment (VI). Study design: cross-sectional research. Methods: The study was conducted with 1,355 visually impaired adults over 45 years old, recruited from a Rehabilitation Hospital in China. Visual impairment is diagnosed by a doctor according to guidelines. Data was analyzed using multiple correspondence and logistic regression analysis. This research represents an important step towards the development of empirically based practical suggestions for decision-makers and health professionals that support visually impaired middle-aged and elderly people to participate in physical exercise and weight management when needed. Results: Of the 1335 middle aged and elderly adults with VI, a total of 154 (11.5%) developed CHD. Statistical analysis based on age grouping indicated that hypertension, diabetes, blindness, gentle and moderate activity were shown to have a strong association with development of CHD. In addition, fasting plasma glucose, heart rate (<60), and BMI were important risk factors for CHD in the middle-aged group and the elderly group respectively.Conclusion: Suggestions for related policy changes should focus on the social and environmental aspects. This includes developing a more accessible and inclusive environments and providing meaningful information about physical activity and weight management to middle-aged and elderly people with visually impaired.

Download Full-text

Clinical features of COVID-19 patients with comorbid coronary heart disease

10.21203/rs.3.rs-129449/v1 ◽

2020 ◽

Author(s):

Hang Yang ◽

RUI GUO ◽

Lincheng Yang ◽

Ruitao Zhang ◽

Yunpeng Ling ◽

...

Keyword(s):

Risk Factors ◽

Coronary Heart Disease ◽

Regression Analysis ◽

Heart Disease ◽

Critical Illness ◽

Lymphocyte Count ◽

Myocardial Injury ◽

Factors Associated ◽

History Of ◽

Wbc Count

Abstract Background: In addition to the lungs, the coronavirus disease 2019 (COVID-19) also affects multiple organs throughout the body. The relationship between COVID-19 infection and cardiovascular disease, and the mechanisms by which this disease causes damage to the cardiovascular system are unclear. Coronary heart disease (CHD) is one of the common comorbidities of COVID-19, but there is insufficient evidence for its clinical features and impact on clinical outcomes. The aim of this study was to analyze the clinical characteristics of COVID-19 patients with comorbid CHD and the possible risk factors for the occurrence of critical illness. Methods: A single-center, retrospective study was conducted to analyze COVID-19 patients admitted to the Sino-French New City Campus of Tongji Hospital in Wuhan, Hubei Province and treated by the Peking University National Medical Assistance Team between January 29 and March 10, 2020. Patients testing positive for SARS-CoV-2 viral nucleic acid in nasopharyngeal swab specimens and who had comorbid CHD, were included in the study. Clinical data and laboratory test results of eligible patients were collected, and the factors associated with the occurrence of critical illness among these patients were evaluated. Results: A total of 205 patients were enrolled in this study, including 20 CHD patients and 185 non-CHD patients. The mean age was 66.7 years. Compared to non-CHD patients, more CHD patients had comorbid hypertension and diabetes (P < 0.05). In terms of laboratory tests, the CHD group did not differ significantly from the non-CHD group in blood routine, blood chemistry, and various inflammatory cytokines. More CHD patients experienced myocardial injury (25% vs 8.1% P < 0.031) and CHD patients were more likely to progress to critical illness (40% vs 16.8%P = 0.012). Univariate logistic regression analysis indicated that a history of CHD, occurrence of myocardial injury, high white blood cell (WBC) count, low lymphocyte count, and elevated levels of Cr, ferritin, IL-2R, IL-8 at admission were factors associated with the occurrence of critical illness. Multivariate regression analysis found that a history of CHD（OR=3.529, 95% CI =1.032-12.075, P =0.044），high WBC count（OR=1.289, 95% CI =1.136-1.463, P＜0.001） and low lymphocyte count（OR=0.215, 95% CI =0.075-0.616, P =0.004）were independent factors for the occurrence of critical illness among COVID-19 patients. Conclusion: COVID-19 patients with comorbid CHD commonly exhibited myocardial injury and were prone to developing critical illness. Among COVID-19 patients, a history of CHD，high WBC count and low lymphocyte count were independent risk factors for the occurrence of critical illness. Greater attention and vigilance are needed in this regard during clinical practice.

Download Full-text

Risk Factors for COVID-19 in Patients with Hypertension

Canadian Journal of Infectious Diseases and Medical Microbiology ◽

10.1155/2021/5515941 ◽

2021 ◽

Vol 2021 ◽

pp. 1-9

Author(s):

Xinxin Wang ◽

Haihua Zhang ◽

Huan Du ◽

Ruina Ma ◽

Yandong Nan ◽

...

Keyword(s):

Risk Factors ◽

Coronary Heart Disease ◽

Risk Factor ◽

Heart Disease ◽

Neutrophil Count ◽

Pulmonary Infection ◽

Laboratory Data ◽

Clinical Manifestations ◽

Factors Associated ◽

High Risk Factor

Background. Hypertension, as the most common comorbidity for patients with coronavirus disease 19 (COVID-19), has resulted in cases with more severe symptoms and higher mortality. The risk factors associated with COVID-19 in patients with hypertension are unknown. Methods. All the available and confirmed patients with COVID-19 from February 3 to March 10, 2020, were enrolled from Huoshenshan Hospital, Wuhan, China. The demographic characteristics, clinical manifestations, laboratory data, radiological assessments, and treatments on admission were extracted and compared. Univariate and multivariate logistic regression methods were used to explore risk factors associated with COVID-19 in patients with hypertension and the severity of the cohort. Results. A total of 430 available patients with COVID-19 were enrolled in the study, including 151 eligible patients with COVID-19 and hypertension. After PSM analysis, 141 patients without hypertension and 141 cases with hypertension were well matched. Compared with cases without hypertension, patients with hypertension were more severe (28.4% vs. 12.1%, p = 0.001 ). In multivariate analysis, we found that neutrophil count (OR: 1.471; p = 0.001 ), coronary heart disease (OR: 5.281; p = 0.011 ), and the level of K+ (OR: 0.273; p < 0.001 ) were associated with patients with hypertension. In addition, the percentage of pulmonary infection volume was larger in cases with hypertension (4.55 vs. 5.8, p = 0.017 ) and was a high risk factor for severe COVID-19 in patients with hypertension (OR: 1.084; p < 0.001 ). Conclusion. On admission, coronary heart disease, neutrophil count, and the level of K+ were associated with COVID-19 patients with hypertension. The percentage of the pulmonary infection volume was significantly larger in COVID-19 patients with hypertension and was a risk factor for COVID-19 severity of the cohort.

Download Full-text

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

10.21203/rs.3.rs-23204/v1 ◽

2020 ◽

Author(s):

Can Chen ◽

Danying Yan ◽

Yuqing Zhou ◽

Guo Tian ◽

Jie Wu ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Disease ◽

Coronary Heart Disease ◽

Heart Disease ◽

Respiratory Failure ◽

Clinical Symptoms ◽

Meta Analysis ◽

Fatal Outcome ◽

Smoking History ◽

Factors Associated

Abstract Background: The COVID-19 infection has caused 111652 deaths worldwide as of 13 April 2020. Risk factors for fatal outcomes of COVID-19 have varied across studies due to limited samples and have lacked effective qualitative and quantitative measurements. We performed a meta-analysis to evaluate risk factors for fatal outcomes of COVID-19.Methods: Data on demographic, clinic, laboratory findings and complications were extracted. Quantitative and qualitative synthesis was conducted for weighted-mean-difference (WMD) and odds-ratio (OR).Results: A total of 30 studies involving 5741 survivors and 1670 deaths were included. The death cases were significantly older than survivors (WMD=15.36, 95% CI: 12.90-17.82), male and smoking history showed higher risk to develop fatal outcome (OR=3.37, 95% CI: 2.27-5.01; OR=1.37, 95% CI: 1.02-1.83, respectively). The clinical symptoms including dyspnea (OR=4.63, 95% CI: 2.85-7.54), hemoptysis (OR=3.11, 95% CI: 1.26-7.56), malaise (OR=2.44, 95% CI: 1.49-3.97). comorbidities with coronary heart disease (OR=4.36, 95% CI: 1.91-9.97), COPD (OR=3.70, 95% CI: 2.03-6.73) and cardiovascular disease (OR=3.45, 95% CI: 2.54-4.70). Compared to survivors, many laboratory indexes increased in deaths group, including serum ferritin (WMD=741.47, 95% CI: 566.77-916.16), lactate dehydrogenase (WMD=226.86, 95% CI: 177.08-276.64) and myoglobin (WMD=102.58, 95% CI: 65.12-140.04), and the decreased indexes included PaO2/FiO2 (WMD=-71.61, 95% CI: -134.11 to -9.11), platelets (WMD=-41.09, 95% CI: -47.33 to -34.85) and PaO2 (WMD=-26.09, 95% CI: -38.9 to -13.29). Main complications contributed to the fatal outcome included sepsis (OR=184.61, 95% CI: 33.43-1019.42), shock (OR=133.76, 95% CI: 36.86-485.34) and respiratory failure (OR=47.37, 95% CI: 20.65-108.66). Conclusion: The main risk factors associated with fatal outcome of COVID-19 involved male, older age, smoking history, chronic medical conditions including coronary heart disease, COPD and cardiovascular disease, clinical symptoms including dyspnea, hemoptysis and malaise, the increased laboratory indexes including serum ferritin, lactate dehydrogenase and myoglobin, the decreased indexes including PaO2/FiO2, platelets and PaO2, main complications including sepsis, shock and respiratory failure. These factors could be considered in triaging patients and allocating medical resources when such medical resources are scarce, devising improved protocols for patient diagnosis and management, and developing new drugs and other therapies to treat COVID-19 patients.

Download Full-text